Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography.

E L, Lu L, Li L, Yang H, Schwartz LH, Zhao B.

Acad Radiol. 2018 Nov 28. pii: S1076-6332(18)30477-X. doi: 10.1016/j.acra.2018.10.013. [Epub ahead of print]

PMID:
30502076
2.

Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.

Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, Huang W, Noworolski SM, Young RJ, Shiroishi MS, Kim H, Coolens C, Laue H, Chung C, Rosen M, Boss M, Jackson EF.

J Magn Reson Imaging. 2018 Nov 19. doi: 10.1002/jmri.26518. [Epub ahead of print] Review.

PMID:
30451345
3.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
4.

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.

Kaufman HL, Schwartz LH, William WN Jr, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2245-2261. doi: 10.1007/s00432-018-2738-x. Epub 2018 Aug 21. Review.

PMID:
30132118
5.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

6.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

PMID:
29966725
7.

Artificial intelligence in radiology.

Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL.

Nat Rev Cancer. 2018 Aug;18(8):500-510. doi: 10.1038/s41568-018-0016-5. Review.

8.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

Claret L, Pentafragka C, Karovic S, Zhao B, Schwartz LH, Maitland ML, Bruno R.

Cancer Chemother Pharmacol. 2018 Jul;82(1):49-54. doi: 10.1007/s00280-018-3587-7. Epub 2018 Apr 26.

PMID:
29700575
9.

Lymph node segmentation by dynamic programming and active contours.

Tan Y, Lu L, Bonde A, Wang D, Qi J, Schwartz LH, Zhao B.

Med Phys. 2018 May;45(5):2054-2062. doi: 10.1002/mp.12844. Epub 2018 Apr 1.

PMID:
29500866
10.

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, Mokrane FZ, Lazarovici J, Danu A, Marabelle A, Ribrag V, Michot JM.

Eur J Cancer. 2018 Mar;91:136-144. doi: 10.1016/j.ejca.2017.12.015.

PMID:
29360605
11.

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E; Alliance for Clinical Trials on Oncology.

BMC Cancer. 2017 Jul 27;17(1):505. doi: 10.1186/s12885-017-3441-z.

12.

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.

Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, Danu A, Edeline V, Marabelle A, Ribrag V, Michot JM.

J Nucl Med. 2018 Jan;59(1):15-24. doi: 10.2967/jnumed.117.193011. Epub 2017 Jun 8.

13.

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL.

Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092.

14.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

15.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review.

16.

A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies.

Chang PD, Malone HR, Bowden SG, Chow DS, Gill BJA, Ung TH, Samanamud J, Englander ZK, Sonabend AM, Sheth SA, McKhann GM 2nd, Sisti MB, Schwartz LH, Lignelli A, Grinband J, Bruce JN, Canoll P.

AJNR Am J Neuroradiol. 2017 May;38(5):890-898. doi: 10.3174/ajnr.A5112. Epub 2017 Mar 2.

17.

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2017 Feb 17;7:41197. doi: 10.1038/srep41197. No abstract available.

18.

Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al.

Brown KT, Do R, Gönen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson K, Garcia AR, Beattie CM, Zhao B, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK.

J Clin Oncol. 2017 Jan 10;35(2):258-259. Epub 2016 Oct 23. No abstract available.

PMID:
28056199
19.

Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings.

Lu L, Ehmke RC, Schwartz LH, Zhao B.

PLoS One. 2016 Dec 29;11(12):e0166550. doi: 10.1371/journal.pone.0166550. eCollection 2016.

20.

Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study.

Li Q, Liang Y, Huang Q, Zong M, Berman B, Gavrielides MA, Schwartz LH, Zhao B, Petrick N.

Med Phys. 2016 Dec;43(12):6608.

21.

High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.

Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O'Connor OA.

J Hematol Oncol. 2016 Nov 30;9(1):132.

22.

A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology.

Yang H, Schwartz LH, Zhao B.

Tomography. 2016 Dec;2(4):406-410. doi: 10.18383/j.tom.2016.00223.

23.

Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging.

Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, Kauczor HU, Schwartz LH, Haberkorn U, Flechsig P.

J Nucl Med. 2017 Feb;58(2):282-287. doi: 10.2967/jnumed.116.179648. Epub 2016 Sep 22.

24.

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860. Erratum in: Sci Rep. 2017 Feb 17;7:41197.

25.

Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH.

J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858.

26.

Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Flechsig P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J, Rieser M, Warth A, Kauczor HU, Schwartz LH, Haberkorn U, Giesel FL.

Mol Imaging Biol. 2017 Apr;19(2):315-322. doi: 10.1007/s11307-016-0996-z.

PMID:
27539308
27.

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.

Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, de Vries E.

Eur J Cancer. 2016 Jul;62:138-45. doi: 10.1016/j.ejca.2016.03.082. Epub 2016 May 26. Review.

28.

RECIST 1.1-Update and clarification: From the RECIST committee.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L.

Eur J Cancer. 2016 Jul;62:132-7. doi: 10.1016/j.ejca.2016.03.081. Epub 2016 May 14.

29.

Reproducibility of radiomics for deciphering tumor phenotype with imaging.

Zhao B, Tan Y, Tsai WY, Qi J, Xie C, Lu L, Schwartz LH.

Sci Rep. 2016 Mar 24;6:23428. doi: 10.1038/srep23428.

30.

Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

Pietanza MC, Hellmann MD, Fiore JJ, Smith-Marrone S, Basch EM, Schwartz LH, Ginsberg MS, Shouery M, Newman SK, Shaw M, Rogak LJ, Lash AE, Hilden P, Kris MG.

J Thorac Oncol. 2016 Jun;11(6):890-9. doi: 10.1016/j.jtho.2016.02.018. Epub 2016 Mar 8.

31.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH.

JAMA Oncol. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315.

32.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

33.

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D'Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O'Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK.

J Clin Oncol. 2016 Jun 10;34(17):2046-53. doi: 10.1200/JCO.2015.64.0821. Epub 2016 Feb 1.

34.

Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.

Hyun O J, Luber BS, Leal JP, Wang H, Bolejack V, Schuetze SM, Schwartz LH, Helman LJ, Reinke D, Baker LH, Wahl RL.

J Nucl Med. 2016 May;57(5):735-40. doi: 10.2967/jnumed.115.162412. Epub 2016 Jan 21.

35.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML.

Clin Transl Sci. 2016 Feb;9(1):43-50. doi: 10.1111/cts.12384. Epub 2016 Jan 21.

36.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

37.

Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer.

Glastonbury CM, Bhosale PR, Choyke PL, D'Orsi CJ, Erasmus JJ, Gill RR, Mukherji SK, Panicek DM, Schwartz LH, Subramaniam RM, Sullivan DC.

Radiology. 2016 Jan;278(1):11-2. doi: 10.1148/radiol.2015151563. No abstract available.

38.

Semiautomatic segmentation of liver metastases on volumetric CT images.

Yan J, Schwartz LH, Zhao B.

Med Phys. 2015 Nov;42(11):6283-93. doi: 10.1118/1.4932365.

39.

Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib.

Zabor EC, Heller G, Schwartz LH, Chapman PB.

Clin Cancer Res. 2016 Mar 15;22(6):1341-7. doi: 10.1158/1078-0432.CCR-15-1441. Epub 2015 Oct 21.

40.

Hybrid detection of lung nodules on CT scan images.

Lu L, Tan Y, Schwartz LH, Zhao B.

Med Phys. 2015 Sep;42(9):5042-54. doi: 10.1118/1.4927573.

PMID:
26328955
41.

Reply to G. Keramida et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2015 Dec 1;33(34):4121-2. doi: 10.1200/JCO.2015.63.2125. Epub 2015 Aug 24. No abstract available.

PMID:
26304890
42.

Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography.

Meignan M, Hutchings M, Schwartz LH.

Oncologist. 2015 Aug;20(8):890-5. doi: 10.1634/theoncologist.2015-0036. Epub 2015 Jul 14. Review. No abstract available.

43.

Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.

Flechsig P, Zechmann CM, Schreiweis J, Kratochwil C, Rath D, Schwartz LH, Schlemmer HP, Kauczor HU, Haberkorn U, Giesel FL.

Eur J Radiol. 2015 Aug;84(8):1593-1600. doi: 10.1016/j.ejrad.2015.04.009. Epub 2015 May 8.

PMID:
25999064
44.

Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.

Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, Perdue JJ, Terrell DR, Vesely SK, George JN.

Am J Hematol. 2015 Aug;90(8):709-14. doi: 10.1002/ajh.24060. Epub 2015 May 28.

45.

Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under "No Change" Conditions.

McNitt-Gray MF, Kim GH, Zhao B, Schwartz LH, Clunie D, Cohen K, Petrick N, Fenimore C, Lu ZQ, Buckler AJ.

Transl Oncol. 2015 Feb;8(1):55-64. doi: 10.1016/j.tranon.2015.01.001.

46.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD.

J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. No abstract available.

PMID:
25691678
47.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

48.

MR/ultrasound fusion-guided biopsy in prostate cancer: what is the evidentiary standard?

Schwartz LH, Basch E.

JAMA. 2015 Jan 27;313(4):367-8. doi: 10.1001/jama.2014.17943. No abstract available.

PMID:
25626034
49.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2014 Sep 20;32(27):3048-58. Erratum in: J Clin Oncol. 2016 Jul 20;34(21):2562.

50.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute.

J Clin Oncol. 2014 Sep 20;32(27):3059-68.

Supplemental Content

Loading ...
Support Center